Born in France, Les Lilas, on 25 th October 1978, Dr. Alain TOLEDANO, apart from a few years in the centre of the country, has spent most of his life in the Paris region.
His medical studies took place at the Xavier Bichat Faculty of Medicine of the René Descartes-Paris VII University from 1995 to 2001, followed by his internship at the Tours and Orléans Hospitals from 2001 to 2005, where he obtained his Doctorate (Thèse de médecine) at the François Rabelais University.
Alongside his medical studies he also obtained an M.Sc. degree in Biochemistry and several other university diplomas including one in cervico-facial oncology.
Dr. Toledano has had the opportunity therefore to work in numerous Oncology Centres in France, with their varied cultures and resources, and more particularly, in Anti-Cancer centres (Institut Curie, Paris), University Hospitals and private clinics in a wide variety of regions: Franche Comté, Rhône Alpes, Pas de Calais, Provence, where he has been able to develop many collaborations and instigate a considerable number of cancer clinical research programmes.
In 2003, he was already much involved in a number of pedagogical and associative groups. For two years, he chaired the SFJRO (Société Française des Jeunes Oncologues, the French Society of Young Oncologists), during which time he organised numerous national congresses for specialisms interns.
In 2005, aged 26, he was appointed Chef de Clinique des Hôpitaux de Paris (Senior Lecturer) at the Pierre et Marie University Hospital, Hôpital Tenon, Paris. During this period, he completed his research into breast, prostate and head and neck cancers as well as into the combination of chemotherapy and radiotherapy.
Dr. Toledano’s dedication to teaching and pedagogy has led him to putting in place bibliographical courses; he also gives lectures regularly at the Faculty of Medicine.
In 2005, he was awarded the Mallet Medal for Oncologist Radiotherapists’ scientific papers at the Antoine Beclère Centre as well as several other national scientific prizes. He won the AROQ (Association de Radio Oncologie Québecoise) prize while in Montreal on a professional visit, a close partnership that continues to this day.
Dr. Alain Toledano founded the CORP (the Paris Oncologists Radiotherapists Club) in 2007, that he chaired until 2011, where all the Ile de France specialists in this discipline meet up regularly, to share their experiences and discuss the most recent innovations in the field of Oncology Radiology.
He is also a member of numerous co-operative research groups: ASTRO (American Society of Radiotherapy), ESTRO (European Society of Radiotherapy) and is a founder member and one time treasurer of AFCOR (Association de Formation Continue en Oncology Radiothérapie), the national organism for on-going training in Oncology Radiotherapy.
His dedication to collective work can be seen in his involvement in numerous Cancerology Clubs, as well as in both national and international training programmes for both cancer specialists and patients.
Since 2007, Dr.Toledano has been a specialist at the Hartmann Radiotherapy Centre, Hauts de Seine, where he continues to take an active part in the introduction of high precision technologies and the development of a modern, state of the art Radiotherapy.
Since 2008, he has been the chief Cancer Specialist at the American Hospital in Paris, where he delivers chemotherapy treatments and participates in the strategic development programmes.
He is called upon, in his capacity as expert advisor, by the HAS (Haute Autorité de Santé, the High Authority for Health), the Inca (Institution National de Cancer), the AFSSAPS (Agence Française du Médicament, the French Drugs Agency) and the Pharmaceutical Industry. Dr.Toledano is also a member of the scientific councils of numerous medical journals such as La Lettre du Cancérologue (The Cancerologist’s Letter) and from 2007 to 2011 he was the editor in chief of the weekly journal, France Cancer.
Since 2012, he has been the chair of the Haute Seine Nord Institute of Oncology Medical Council that groups together the cancerology departments of the American Hospital in Paris, the Hartmann-Ambroise Paré – Pierre Cherest in Neuilly, the Franco-British Hospital in Levallois and the Centre de Radiothérapie Hartmann (the Hartmann Radiotherapy Centre).
In 2012, Dr.Toledano founded the Société Française d’Onco-Esthétique (French Society for Onco-Aesthetics), to train beauticians/aestheticians and bring comfort and well-being to patients
He was also a founder member of the Biology of Cancer Master Classes and has implemented Oncogenetic programmes in the Hauts de Seine.
2012 was particularly devoted to grouping together medical specialists and cancerologists ; the “Medicine of Cancers” and “Biology of Cancers” scientific sessions will be followed this year by the very first “Heart and Cancer” scientific sessions.
Since 2008, Dr.Toledano has been giving lectures on Oncogeriatrics at the Faculty of Medicine and remains much involved in University life.
Together with his partners, Dr. Hanah Lamallem and Dr. Marc Bollet, they form a dynamic group of complementary personalities whose common on-going ideal of a personalised cancer treatment for each individual patient is based both on up-to-the-minute research and methods and the very latest state of the art equipment.
Their team is also made up of secretaries, physicists, computer scientists, clinical researchers, who all work hand in hand in an attempt to defeat cancer.
- Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities: Long term results of the ARCOSEIN multicenter randomized study
Toledano A, Garaud P, Serin D, Fourquet A, Bosset JF, Breteau N, Body G, Azria D, Le Floch O, Calais G -Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):324-32
- Does concurrent radio-chemotherapy impact on cosmetic results in the adjuvant setting after breast-conserving surgery? Long-term results of the the ARCOSEIN multicenter phase III study: Patients’ and doctors’ views.
Toledano A, Bollet MA, Fourquet A, Azria D, Gligorov J, Garaud P, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G – Int J Radiat Oncol Biol Phys. 2007; 68(1)66-72
- In reply to Drs. Munshi and Jalali.
Toledano A, Calais G, Fourquet A, Azria D
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):314-5
- Concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: clinical results of the ARCOSEIN phase III randomized trial
Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, and Calais G – J Clin Oncol 2007; Feb 1;25(4): 405-10
- PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup
Toledano A, Chauveinc L, , Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM – Brachytherapy. 2006 Apr-Jun;5(2):122-6
- La Radiochimiothérapie concomitante après chirurgie conservatrice du sein augmente la toxicité tardive
Toledano A, Garaud P, Serin D, Fourquet A, Bosset JF, Breteau N, Body G, Azria D, Le Floch O, Calais G – Cancer Radiother. 2006 Apr 20
- Rebonds de PSA après curiethérapie de prostate
Toledano A, Chauveinc L, , Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM – Cancer Radiother 2006-Dec 15
- Dynamique et évaluation de la formation des internes en radiothérapie en France en 2005
Kantor G, Huguet F, Toledano A, Lafond C, Quero L, Servagi S, Gérard JP, Bey P – Cancer Radiother 2005 ; 9 : 435-443
- La formation des internes en radiothérapie-oncologie
Kantor G, Rivera S, Lafond C, Duparc A, Huguet F, Toledano A, Servagi S, Martin E, Mornex F, Bolla M, Bey P – Oncologie 2007 (9)1 :21-22
- [Elevation of PSA after prostate radiotherapy: rebound or biochemical recurrence?].
Toledano A, Chiche R, Lamallem H, Kanoui A, Beley S, Thibault F, Sèbe P. Prog Urol. 2008 Oct;18(9):557-61. Epub 2008 Jul 26. Review. French.
More publications on PubMed.gov